RG
RARE icon

Rathbones Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Rathbones Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,550
Closed -$212K – 433
2022
Q2 		$212K Hold
3,550
– – ﹤0.01% 383
2022
Q1 		$258K Hold
3,550
– – ﹤0.01% 373
2021
Q4 		$299K Hold
3,550
– – ﹤0.01% 363
2021
Q3 		$320K Buy
3,550
+80
+2% +$7.23K ﹤0.01% 347
2021
Q2 		$331K Buy
+3,470
New +$362K ﹤0.01% 353

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Rathbones Group's RARE Position: Q3 2022 in Review

Rathbones Group sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2022, closing a stake of 3,550 shares — an estimated $212K sold.

Rathbones Group first reported a position in RARE in Q2 2021 and held it in 5 quarters. The position peaked at $331K in Q2 2021. 232 funds tracked by Wall St. Rank hold RARE as of Q3 2022.

  • Rathbones Group reported no remaining Ultragenyx Pharmaceutical position as of Q3 2022 after selling out during the quarter.
  • Rathbones Group sold 3,550 Ultragenyx Pharmaceutical shares in Q3 2022, an estimated $212K.
  • Rathbones Group first reported a position in Ultragenyx Pharmaceutical in Q2 2021 and held it in 5 quarters.
  • Rathbones Group's Ultragenyx Pharmaceutical position peaked at $331K in Q2 2021.
  • 232 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2022.

Based on Rathbones Group's 13F filing for Q3 2022, filed 3 Nov 2022.